TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24495792
Drug: Telmisartan plus
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan plus rosuvastatin (combination group)
Study: 22814578
Drug: Pyridoxine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (50 mg po three times daily)
Study: 16371925
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (two capsules of Oxy-Q containing 480 mg of curcumin and 20 mg of quercetin)
Study: 16371925
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (one capsule of Oxy-Q containing 480 mg of curcumin and 20 mg of quercetin)
Study: 16371925
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (one capsule of Oxy-Q)
Study: 16371925
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (two capsules of Oxy-Q)
Study: 16371925
Drug: Control (placebo)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (placebo) and Low dose (one capsule of Oxy-Q)
Study: 12669769
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of rifampicin, isoniazid, and pyrazinamid (Trifazid)
Study: 12669769
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of rifampicin, isoniazid, and pyrazinamid
Study: 7917561
Drug: Sclerotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy plus nadolol (mean final dose: 82 +/- 31 mg/d)
Study: 380184
Drug: iopronic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopronic acid (4.5 g Oravue, Squibb)
Study: 380184
Drug: iopanoic acid
Normalized name: Iopanoic Acid
DrugBank: Iopanoic acid (DB08946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iopanoic acid (3 g Telepaque, Winthrop)
Study: 30782258
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg moclobemide tablets (Jelfa)
Study: 30782258
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Aurorix tablets (Hoffmann la Roche)
Study: 29109107
Drug: Web site
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Web site with vaccine information and interactive social media components (VSM)
Study: 29109107
Drug: Web site
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Web site with vaccine information (VI)
Study: 19426108
Drug: Thrombin solution
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin solution (100 unit/ml) irrigation
Study: 19426108
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution irrigation with anti-platelet medication
Study: 19426108
Drug: Thrombin solution
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin solution irrigation with anti-platelet medication
Study: 9719164
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% albumin infusion 100 ml three times per week for 2 weeks
Study: 9719164
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no albumin infusion)
Study: 9719164
Drug: Four weeks
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four weeks after withdrawal of albumin infusion
Study: 2673623
Drug: Moclobemide 200
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 200 mg t.i.d.
Study: 2673623
Drug: Tranylcypromine 10
Normalized name: tranylcypromine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine 10 mg b.i.d.
Study: 1273208
Drug: Haloperidol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 0.25 mg
Study: 23138261
Drug: Haloperidol 0.5
Normalized name: haloperidol 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 0.5 mg
Study: 29020329
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (VITD3) 50000 IU monthly plus daily multivitamin containing VITD3 400 IU and calcium 162 mg
Study: 29020329
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus daily multivitamin containing VITD3 400 IU and calcium 162 mg
Study: 20513595
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of heparin + a glycoprotein IIb/IIIa inhibitor
Study: 16035144
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 5 mg
Study: 7822629
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 10 mg
Study: 16035144
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 15 mg
Study: 9527752
Drug: Clorazepate-dipotassium (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate-dipotassium (20 mg)
Study: 7614911
Drug: Aspartame (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (50 mg/kg)
Study: 775990
Drug: Loridine-Keflex prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loridine-Keflex prophylaxis (antibiotics)
Study: 29275697
Drug: General functioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: General functioning improvement treatments
Study: 24549371
Drug: JNJ‐39758979 (H(4)R
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐39758979 (H(4)R antagonist)
Study: 23032552
Drug: Mexiletine 200
Normalized name: mexiletine 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine 200 mg orally 3 times daily for 4 weeks
Study: 9389860
Drug: Rocuronium 1
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 1 ml (10 mg)
Study: 9389860
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl 1 ml (placebo)
Study: 9389860
Drug: Rocuronium (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (second injection)
Study: 7948796
Drug: Amrinone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (2 mg/kg bolus during CPB)
Study: 31198594
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (600 μg)
Study: 24564041
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) therapy plus medications (analgesics, nonsteroidal anti-inflammatory - diclofenac sodium)
Study: 24564041
Drug: Standard medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medications (analgesics, nonsteroidal anti-inflammatory - diclofenac sodium)
Study: 22247928
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% lidocaine cream
Study: 16476120
Drug: Supportive therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapies only (Control)
Study: 12897047
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg/day of Zn as Zn gluconate)
Study: 9433655
Drug: grepafloxacin 600
Normalized name: grepafloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: grepafloxacin 600 mg once daily for 10 days with theophylline
Study: 9433655
Drug: grepafloxacin 600
Normalized name: grepafloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: grepafloxacin 600 mg once daily for 14 days with warfarin
Study: 8431336
Drug: Free clear
Normalized name: Guaifenesin 100 mg in 5 mL / Dextromethorphan Hydrobromide 10 mg in 5 mL ORAL SOLUTION [Robafen DM Cough Sugar Free Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free clear fluids intake until premedication (mean 388 ml in 6 h before surgery)
Study: 24619763
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 70 mg/week (n=41)
Study: 24619763
Drug: Raloxifene (RAL)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RAL) 60 mg/d (n=37)
Study: 24619763
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional medication (n=47)
Study: 22450724
Drug: Remifentanil (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.02 mg/mL)
Study: 22450724
Drug: Alfentanil 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 1 (0.04 mg/mL)
Study: 22450724
Drug: Alfentanil 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 2 (0.08 mg/mL)
Study: 18208877
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 20 mg PO
Study: 18208877
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone (IVMP) 1,000 mg/day for three days every other month
Study: 18208877
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta-1a (IM IFNbeta-1a) 30 mcg IM weekly
Study: 16436547
Drug: Atomoxetine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (maximum dose 1.8 mg/kg/day; n = 102)
Study: 9429680
Drug: Structured communication
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured communication program (discussion with a nurse, informational pamphlet, daily telephone call)
Study: 2757885
Drug: Inhaled NAAGA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled NAAGA (60 mg thrice daily for 1 week)
Study: 180199
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of adenine arabinoside/kg per day
Study: 180199
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of adenine arabinoside/kg per day
Study: 180199
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of adenine arabinoside/kg per day
Study: 180199
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of adenine arabinoside/kg per day
Study: 31697972
Drug: MSDC-0602K 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSDC-0602K 62.5 mg
Study: 31697972
Drug: MSDC-0602K 125
Normalized name: MSDC-0160
DrugBank: Mitoglitazone (DB11721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSDC-0602K 125 mg
Study: 31697972
Drug: MSDC-0602K 250
Normalized name: MSDC-0160
DrugBank: Mitoglitazone (DB11721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSDC-0602K 250 mg
Study: 31697972
Drug: MSDC-0602K (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSDC-0602K (all doses)
Study: 31783602
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000 IU loading dose of cholecalciferol followed by 4000 IU daily for 16 weeks)
Study: 26228576
Drug: New chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: New chewable benazepril hydrochloride tablet (0.5 mg/kg p.o.)
Study: 26228576
Drug: Branded formulation
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulation (Fortekor®)
Study: 22065305
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of norgestomet implant for 9 days with 500 IU PMSG at implant removal
Study: 22065305
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of norgestomet implant for 9 days without PMSG
Study: 22065305
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without hormonal treatment
Study: 19713152
Drug: AVI-4658 (0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVI-4658 (0.09 mg in 900 microL saline)
Study: 19713152
Drug: AVI-4658 (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVI-4658 (0.9 mg in 900 microL saline)
Study: 15231012
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/day and 5 mg/day
Study: 15231012
Drug: Alendronate (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (combined 5 mg and 10 mg groups)
Study: 15028823
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of alendronate
Study: 9836078
Drug: Bone metabolism
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone metabolism imbalance in IBD patients
Study: 1098888
Drug: Fludrocortisone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (0.3 mg for seven days)
Study: 21606192
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg for 6 months
Study: 20050483
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral handover
Study: 16948972
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg twice a day) and Vitamin E (400 IU per day)
Study: 16948972
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vitamin therapy)
Study: 9435196
Drug: Lisofylline (LSF)
Normalized name: Lisofylline
DrugBank: Lisofylline (DB12406)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisofylline (LSF) at doses of 1, 2, or 3 mg/kg every 24 hr for 3 days by 10 min intravenous infusion
Study: 8010459
Drug: Buprenorphine 0.4
Normalized name: buprenorphine 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.4 mg and indomethacin 50 mg (Group A)
Study: 8010459
Drug: Buprenorphine 0.4
Normalized name: buprenorphine 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.4 mg (Group B)
Study: 8010459
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg (Group C)
Study: 8010459
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (Group D)
Study: 799980
Drug: Isoetharine ('Numotac')
Normalized name: Isoetharine
DrugBank: Isoetharine (DB00221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoetharine ('Numotac') 10 mg
Study: 799980
Drug: Isoetharine ('Numotac')
Normalized name: Isoetharine
DrugBank: Isoetharine (DB00221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoetharine ('Numotac') 20 mg
Study: 25632575
Drug: Medication (Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Aspirin and Panax Notoginseng Saponins)
Study: 21730216
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein intake (median of 30 g/d)
Study: 17341994
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg, titrated to 40 mg at week 4, remained at 40 mg at week 8 and 12
Study: 17341994
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium 50 mg, titrated to 50 mg twice daily at week 8
Study: 17341994
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg, titrated to 320 mg at week 8
Study: 15231078
Drug: Iron administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron administered once a week (60 mg as 300-mg ferrous sulfate tablets)
Study: 15231078
Drug: Iron administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron administered twice a week (60 mg as 300-mg ferrous sulfate tablets)
Study: 15231078
Drug: Iron administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron administered once a day (60 mg as 300-mg ferrous sulfate tablets)
Study: 11727882
Drug: Adolescent group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent group therapy (AGT)
Study: 3326115
Drug: Zopiclone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 2.5 mg
Study: 3326115
Drug: Zopiclone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (various doses)
Study: 25527295
Drug: Fixed-combination bimatoprost/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination bimatoprost/timolol (bim/tim)
Study: 25527295
Drug: Fixed-combination dorzolamide/brimonidine/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination dorzolamide/brimonidine/timolol (dorz/brim/tim)
Study: 22308289
Drug: G-CSF-mobilized peripheral
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF-mobilized peripheral blood mononuclear cells (G-PBMCs)
Study: 20376496
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg before surgery and repeated after 12 hours
Study: 16154698
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg buprenorphine i.v. and placebo pill s.l.
Study: 16154698
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg buprenorphine s.l. and saline 0.9% i.v.
Study: 16154698
Drug: saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline 0.9% i.v. and placebo pill s.l.
Study: 12810244
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1% methyl nicotinate (MN)
Study: 1333087
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg b.d. or q.i.d.)
Study: 3913424
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (gastropulgit) - 2 bags
Study: 3913424
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (commercial product) - 2 bags
Study: 30388596
Drug: Oxandrolone (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (synthetic hormone analog of testosterone)
Study: 29703749
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MSCs and CPCs
Study: 20570237
Drug: Combination intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intravitreal ranibizumab 0.5 mg and topically applied MMC (0.4 mg/mL for 2 min)
Study: 20570237
Drug: Topical MMC
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical MMC (0.4 mg/mL for 2 min) alone
Study: 16009446
Drug: No probucol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No probucol treatment
Study: 10663455
Drug: Intravenous dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dopamine infusion (2 microg/kg/min)
Study: 8860788
Drug: Health promotion
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health promotion intervention (11 weeks of daily circuit training exercise and health lecture-discussions)
Study: 1310160
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with daily cisplatin (6 mg/m² before radiotherapy)
Study: 1310160
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with weekly cisplatin (30 mg/m² on the first day of each treatment week)
Study: 25165427
Drug: 0.075-mg palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075-mg palonosetron
Study: 25165427
Drug: 40-mg aprepitant
Normalized name: aprepitant 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mg aprepitant
Study: 21717516
Drug: Low-dose (72 mg-ECP/day)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose (72 mg-ECP/day)
Study: 21717516
Drug: High-dose (144 mg-ECP/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (144 mg-ECP/day)
Study: 18473194
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) iron supplementation
Study: 18473194
Drug: Erythropoietic Stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietic Stimulating Agents (ESAs)
Study: 17544845
Drug: (223)Ra (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: (223)Ra (50 kBq/kg, 4 intravenous injections every 4 weeks)
Study: 17544845
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 intravenous injections every 4 weeks)
Study: 8579030
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg twice daily)
Study: 15846279
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate (50 mg twice daily)
Study: 25122977
Drug: Marketed stabilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed stabilized stannous fluoride (SnF2) dentifrice (Oral‐B Pro‐Expert, 0.454% SnF2 plus 0.077% NaF)
Study: 9571349
Drug: Fosinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (20 mg/day)
Study: 15059705
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% applied four times a day for 3 days before surgery and 1 hour preoperatively
Study: 15059705
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 1 hour before surgery
Study: 9707165
Drug: Budesonide (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (inhaled glucocorticoid)
Study: 2096345
Drug: Iontophoresis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis of lidocaine hydrochloride 4% solution